Madrigal Pharmaceuticals (MDGL) Competitors

Biogen (NASDAQ:BIIB) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Which has higher valuation & earnings, BIIB or MDGL?

Biogen has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.82B	1.95	$1.63B	$10.13	12.89
Madrigal Pharmaceuticals	$317.38M	20.48	-$373.63M	-$18.05	-16.22

Does the media favor BIIB or MDGL?

In the previous week, Biogen had 20 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 28 mentions for Biogen and 8 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 1.62 beat Biogen's score of 1.34 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	22 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Madrigal Pharmaceuticals	8 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Does the MarketBeat Community favor BIIB or MDGL?

Biogen received 1358 more outperform votes than Madrigal Pharmaceuticals when rated by MarketBeat users. Likewise, 71.28% of users gave Biogen an outperform vote while only 68.03% of users gave Madrigal Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Biogen	Outperform Votes 1824 71.28%	Underperform Votes 735 28.72%
Madrigal Pharmaceuticals	Outperform Votes 466 68.03%	Underperform Votes 219 31.97%

Do analysts rate BIIB or MDGL?

Biogen presently has a consensus target price of $191.30, suggesting a potential upside of 46.53%. Madrigal Pharmaceuticals has a consensus target price of $416.33, suggesting a potential upside of 42.21%. Given Biogen's higher possible upside, equities analysts plainly believe Biogen is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	0 Sell rating(s)	20 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.38
Madrigal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

Do institutionals & insiders hold more shares of BIIB or MDGL?

87.9% of Biogen shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 0.2% of Biogen shares are held by insiders. Comparatively, 21.5% of Madrigal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Is BIIB or MDGL more profitable?

Biogen has a net margin of 16.87% compared to Madrigal Pharmaceuticals' net margin of 0.00%. Biogen's return on equity of 14.98% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	16.87%	14.98%	8.76%
Madrigal Pharmaceuticals	N/A	-71.78%	-53.25%

Which has more volatility & risk, BIIB or MDGL?

Biogen has a beta of 0.12, suggesting that its share price is 88% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -0.91, suggesting that its share price is 191% less volatile than the S&P 500.

Summary

Biogen beats Madrigal Pharmaceuticals on 13 of the 18 factors compared between the two stocks.